Topic · Cellular and Molecular Neuroscience · Neuroscience
Genetic Neurodegenerative Diseases
OpenAlex topic; a paper is listed when OpenAlex scores it at least 0.5 for this topic.
294 papers
- GeneticsScientific ReportsPeer-reviewed10 citations
- Molecular BiologyACS Chemical NeurosciencePeer-reviewed
Differential Effects of Posttranslational Modifications on the Membrane Interaction of Huntingtin Protein
Zhidian Zhang, Charlotte Julie Caroline Gehin, Luciano A. Abriata…·Hilal Ahmed Lashuel
This study investigates how posttranslational modifications affect the membrane interaction and helical structure of the N-terminal fragment of the huntingtin protein.
4 citations - Cell BiologyMolecular CellPeer-reviewed
Autophagy preferentially degrades non-fibrillar polyQ aggregates
Dorothy Yanling Zhao, Felix J.B. Bäuerlein, Itika Saha…·Florian Wilfling
This study shows autophagosomes preferentially degrade non-fibrillar polyQ aggregates by interacting with p62, while amyloid fibrils evade clearance due to their non-deformable structure.
57 citationstop 2% - NeuroscienceEBioMedicinePeer-reviewed
The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ
Xuexin Li, Ivó H. Hernández, Seda Koyuncu…·Óscar Fernández-Capetillo
The paper identifies clofazimine as a drug that reduces polyQ toxicity by activating PPARγ, improving mitochondrial function in models of polyQ diseases.
5 citations - GeneticsNature CommunicationsPeer-reviewed
PMS1 as a target for splice modulation to prevent somatic CAG repeat expansion in Huntington's disease
Zachariah L. McLean, Dadi Gao, Kevin Correia…·James F. Gusella
This study shows splice modulators like branaplam reduce HTT CAG repeat expansion by affecting PMS1 expression, suggesting PMS1 as a new therapeutic target for Huntington's disease.
48 citationstop 1% - NeuroscienceNeurobiology of DiseasePeer-reviewed
BDNF and TRiC-inspired Reagents Rescue Cortical Synaptic Deficits in a Mouse Model of Huntington's Disease
Yingli Gu, Alexander Pope, Charlene Smith-Geater…·Chengbiao Wu
This study shows that BDNF and TRiC-inspired reagents can rescue synaptic deficits in HD mouse models.
8 citations - NeuroscienceJournal of NeurosciencePeer-reviewed
Impairment of the glial phagolysosomal system drives prion-like propagation in a Drosophila model of Huntington's disease
Graham H. Davis, Aprem Zaya, Margaret M.P. Pearce
This study shows that mutant huntingtin aggregates impair glial phagocytosis and phagolysosomal function in Drosophila, leading to prion-like propagation of aggregates and neurodegeneration.
7 citations - NeuroscienceNeurobiology of DiseasePeer-reviewed
Progressive alterations in polysomal architecture and activation of ribosome stalling relief factors in a mouse model of Huntington's disease
Eva Martin‐Solana, Irene Díaz‐López, Yamina Mohamedi…·Marı́a Rosario Fernández-Fernández
This study examines polysomal architecture changes in a mouse model of Huntington's disease, finding compacted polysomes and increased expression of ribosome stalling relief factors.
6 citations - NeuroscienceBrain and BehaviorPeer-reviewed
Disentangling the neurobiological bases of temporal impulsivity in Huntington's disease
Helena Pardina-Torner, Audrey E. De Paepe, Clara Garcia‐Gorro…·Estela Càmara
This study investigates temporal impulsivity in Huntington's disease using a Delay Discounting task and diffusion-tensor imaging to identify white matter correlates.
6 citations - NeuroscienceMolecular TherapyPeer-reviewed
ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
Kristen H. Schuster, Annie J. Zalon, Danielle M. DiFranco…·Hayley S. McLoughlin
This study shows that ASO treatment rescues oligodendrocyte dysfunction in SCA3 mice by targeting mutant ATXN3, suggesting potential for glial-targeted therapies in neurodegenerative diseases.
24 citations - NeuroscienceBrainPeer-reviewed
A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease
Sarah G. Aldous, Edward J. Smith, Christian Landles…·Gillian P. Bates
This study shows that reducing MSH3 in Huntington's disease mouse models prevents somatic CAG repeat expansion but does not accelerate disease onset, suggesting somatic expansion may not be required for pathogenesis.
63 citationstop 1% - Molecular BiologyEMBO Molecular MedicinePeer-reviewed
Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression
Anat Bahat, Elad Itzhaki, Benjamin Weiss…·Rivka Dikstein
This study identifies small molecules that lower mutant huntingtin levels, improving HD symptoms and delaying disease progression in mice.
6 citations - NeuroscienceNature GeneticsPeer-reviewed
Cell Type Specific CAG Repeat Expansions and Toxicity of Mutant Huntingtin in Human Striatum and Cerebellum
Kärt Mätlik, Matthew Baffuto, Laura Kus…·Nathaniel Heintz
The paper investigates CAG repeat expansions and their association with cell death in specific brain regions in Huntington's disease using molecular profiling.
150 citationstop 1% - Molecular BiologyMolecular CellPeer-reviewed
CAG repeat expansions create splicing acceptor sites and produce aberrant repeat-containing RNAs
Rachel Anderson, Michael R. Das, Yeonji Chang…·Ankur Jain
This study identifies that CAG repeat expansions create new splice acceptor sites, leading to aberrant repeat-containing RNAs that are translated via canonical AUG-initiated mechanisms.
- NeuroscienceNeurobiology of DiseasePeer-reviewed
Different Purkinje cell pathologies cause specific patterns of progressive ataxia in mice
Dick Jaarsma, María B. Birkisdóttir, Randy van Vossen…·Laurens W. J. Bosman
This study shows that different Purkinje cell pathologies in mice lead to distinct patterns of progressive gait ataxia, highlighting the importance of pathological mechanisms in disease progression.
16 citations - NeuroscienceThe FASEB JournalPeer-reviewed
Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3
Maxinne Watchon, Katherine J. Robinson, Luan Luu…·Angela S. Laird
This study shows that sodium butyrate improves symptoms of SCA3 by enhancing autophagy through PKA/AMPK signaling in both cell and zebrafish models.
14 citations - NeuroscienceNeuronPeer-reviewed
Selective Vulnerability of Layer 5a Corticostriatal Neurons in Huntington's Disease
Christina Pressl, Kärt Mätlik, Laura Kus…·Nathaniel Heintz
The paper identifies layer 5a corticostriatal neurons as selectively vulnerable in Huntington's disease using single nucleus RNA sequencing and shows they have extensive mHTT-CAG expansions.
98 citationstop 1% - PhysiologyJournal of Clinical InvestigationPeer-reviewed
Combinatorial chloride and calcium channelopathy in myotonic dystrophy
Lily A. Cisco, Matthew T. Sipple, Katherine M. Edwards…·John D. Lueck
The paper shows that combining chloride and calcium channel dysfunction in mice worsens myotonic dystrophy symptoms, and calcium blockers can improve survival and function.
28 citations - NeuroscienceBrain CommunicationsPeer-reviewed
Mutant HTT protein decreases with CAG repeat expansion: implications for therapeutics and bioassays.
Christian Landles, Georgina F Osborne, Jemima M Phillips…·Gillian P. Bates
The paper shows that mutant HTT levels decrease with CAG repeat expansion, suggesting therapeutic strategies should target HTT1a instead of full-length HTT.
27 citationstop 4% - Cell BiologyJournal of Cellular SignalingPeer-reviewed
One-to-one Benefit provided by Antioxidants to cultured skin Fibroblasts from Friedreich Ataxia patients
Paule Bénit, Malgorzata Rak, Pierre Rustin
This study examines antioxidant effects on FRDA fibroblasts, finding variable responses that may hinder clinical conclusions.
DOI 10.33696/signaling.5.122 - NeuroscienceBrain CommunicationsPeer-reviewed
Long non-coding RNA TUG1 is down-regulated in Friedreich's ataxia.
Mert Koka, Hui Li, Rumana Akther…·Vijayendran Chandran
This study identifies TUG1 as a blood-based biomarker for Friedreich's ataxia, showing its downregulation in patients and correlation with disease severity.
- Genetic & Genomic MedicineParkinsonism & Related DisordersPeer-reviewed
Spinocerebellar ataxia type 2 has multiple ancestral origins
Lucas Schenatto Sena, Gabriel Vasata Furtado, José Luiz Pedroso…·Maria Luiza Saraiva Pereira
The paper identifies eleven distinct ancestral haplotypes associated with SCA2 in South American populations, including an unexpected haplotype with a G allele at rs695871.
7 citations - NeurosciencePLoS ONEPeer-reviewed
ATXN2 is a target of N-terminal proteolysis
This study investigates whether ATXN2 with expanded polyQ domains is a target for N-terminal proteolysis, finding that both normal and expanded polyQ ATXN2 undergo cleavage, with specific sequences modulating this process.
12 citations - GeneticseLifePeer-reviewed
Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease
Doo Eun Choi, Jun Wan Shin, Sophia Zeng…·Jong‐Min Lee
The paper develops base editing strategies to convert CAG to CAA in Huntington's disease, reducing CAG repeat expansion and showing therapeutic potential.
9 citations - NeuroscienceJournal of Neuroscience ResearchPeer-reviewed
A phenotypically robust model of Spinal and Bulbar Muscular Atrophy in Drosophila
Kristin Richardson, Medha Sengupta, Alyson L. Sujkowski…·Sokol V. Todi
This paper develops a Drosophila model of SBMA by expressing human AR with pathogenic polyQ repeats, showing motor neuron degeneration and aggregation linked to androgen dependence.
8 citations - GeneticsFrontiers in GeneticsPeer-reviewed
A model for the dynamics of expanded CAG repeat alleles: ATXN2 and ATXN3 as prototypes
Lucas Schenatto Sena, Renan Barbosa Lemes, Gabriel Vasata Furtado…·Laura Bannach Jardim
The paper develops a mathematical model to simulate the dynamics of CAG repeat expansions in SCA2 and SCA3/MJD, showing how generations pass before alleles are eliminated or fixed.
3 citations - NeuroscienceACS Medicinal Chemistry LettersPeer-reviewed
Highly Potent Peptide Therapeutics To Prevent Protein Aggregation In Huntington s Disease
Anooshay Khan, Cemile Elif Özçelik, Özge Beğli…·Urartu Özgür Şafak Şeker
This study identifies three peptides that inhibit mHtt fibril formation in vitro, offering potential therapeutic leads for Huntington's disease.
8 citations - GeneticsG3 Genes Genomes GeneticsPeer-reviewed
Massive contractions of Myotonic Dystrophy Type 2-associated CCTG tetranucleotide repeats occur via double strand break repair with distinct requirements for helicases
David Papp, Luis C. Hernandez, Theresa A. Mai…·Jane C. Kim
This study investigates the molecular mechanisms of CCTG repeat contractions in DM2 using yeast, showing distinct helicase requirements and chromosomal fragility.
4 citations - NeuroscienceNutritional NeurosciencePeer-reviewed
Trehalose Consumption Ameliorates Pathogenesis in an Inducible Mouse Model of the Fragile X-associated Tremor/Ataxia Syndrome
This study evaluates the therapeutic potential of trehalose in a mouse model of FXTAS, showing it reduces protein aggregation and improves motor function when administered preventively but not when used as a treatment.
7 citations - NeuroscienceNeurobiology of DiseasePeer-reviewed
Early whole-body mutant huntingtin lowering averts changes in proteins and lipids important for synapse function and white matter maintenance in the LacQ140 mouse model
Kai Shing, Ellen Sapp, Adel Boudi…·Kimberly B. Kegel-Gleason
15 citations